Results from Preclinical Studies:
LGM2605 significantly reduced disease progression in multiple rodent fibrosis models
LGM2605 improved overall survival in multiple rodent fibrosis models
LGM2605 demonstrated safety in multiple rodent toxicology studies
LGM2605 PK/PD data in non-human primates
Pre-IND Meeting held with FDA to discuss radiation poisoning development program
LignaMed holds exclusive licenses to the patents for LGM2605 from The Trustees of the University Of Pennsylvania and The Scripps Institute
Robust Intellectual Property: In prosecution patents for methods of use and methods of manufacturing. Allowance received in Australia for Methods of Manufacturing.
Awarded $5.2 million dollar contract from National Institutes of Health to develop LGM2605 as a medical countermeasure agent to treat radiation lung damage from nuclear accident or attack
Awarded $278,000 phase I STTR grant award from National Institutes of Health to develop LGM2605 as a treatment for asthma
Awarded $125,000 phase I SBIR grant award from NASA to develop LGM2605 as a mitigator of space radiation–induced vascular damage. This is part of NASA’s space travel to Mars program.